Nanotechnological approaches for the treatment of placental dysfunction: recent trends and future perspectives

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Chaddha V, Viero S, Huppertz B, Kingdom J. Developmental biology of the placenta and the origins of placental insufficiency. Semin. Fetal Neonatal Med. 9(5), 357–369 (2004).
  MedlineGoogle Scholar
• 2. Mazarico E, Molinet-Coll C, Martinez-Portilla RJ, Figueras F. Heparin therapy in placental insufficiency: systematic review and meta-analysis. Acta Obstet. Gynecol. Scand. 99(2), 167–174 (2020).
  MedlineGoogle Scholar
• 3. Agarwal R, Tiwari A, Wadhwa N, Radhakrishnan G. Placental histopathological findings in pre-term/term and early/late onset small for gestation age: are they significant? Indian J. Pathol. Microbiol. 60(2), 232 (2017).
  MedlineGoogle Scholar
• 4. Ohgiya Y, Nobusawa H, Seino N et al. MR imaging of fetuses to evaluate placental insufficiency. Magn. Reson. Med. Sci. 15(2), 212–219 (2016).
  MedlineGoogle Scholar
• 5. Chappell LC, David AL. Improving the pipeline for developing and testing pharmacological treatments in pregnancy. PLOS Med. 13(11), e1002161 (2016).
  MedlineGoogle Scholar
• 6. Mitchell AA, Gilboa SM, Werler MM et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am. J. Obstet. Gynecol. 205(1), 51.e51–51.e58 (2011).
  Google Scholar
• 7. Buhimschi CS, Weiner CP. Medications in pregnancy and lactation. Obstet. Gynecol. 114(1), 167–168 (2009).
  Google Scholar
• 8. Burkey BW, Holmes AP. Evaluating medication use in pregnancy and lactation: what every pharmacist should know. J. Pediatr. Pharmacol. Ther. 18(3), 247–258 (2013).
  MedlineGoogle Scholar
• 9. Bragazzi NL. Nanomedicine: insights from a bibliometrics-based analysis of emerging publishing and research trends. Medicina 55(12), 785 (2019).
  MedlineGoogle Scholar
• 10. Kim BY, Rutka JT, Chan WC. Nanomedicine. N. Engl. J. Med. 363(25), 2434–2443 (2010).
  Medline CASGoogle Scholar
• 11. Kannan RM, Kannan S. Emerging nanomedicine approaches in obstetrics. Am. J. Obstet. Gynecol. 216(3), 201–203 (2017).
  MedlineGoogle Scholar
• 12. Glassman PM, Muzykantov VR. Pharmacokinetic and pharmacodynamic properties of drug delivery systems. J. Pharmacol. Exp. Ther. 370(3), 570–580 (2019).
  Medline CASGoogle Scholar
• 13. Lu W, Yao J, Zhu X, Qi Y. Nanomedicines: redefining traditional medicine. Biomed. Pharmacother. 134, 111103 (2021).
  Medline CASGoogle Scholar
• 14. Chen T, Liu W, Xiong S et al. Nanoparticles mediating the sustained puerarin release facilitate improved brain delivery to treat Parkinson's disease. ACS Appl. Mater. Interfaces 11(48), 45276–45289 (2019).
  Medline CASGoogle Scholar
• 15. Burton GJ, Fowden AL. The placenta: a multifaceted, transient organ. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 370(1663), 20140066 (2015). •• This manuscript discusses the placenta's transient and diverse role in fetal development. It emphasizes the placenta's anatomical modifications to efficiently exchange maternal and fetal circulations and give oxygen and nutrients to the developing fetus, especially the brain. The article also discusses how placental hormones affect maternal metabolism and energy reserves during pregnancy and postpartum.
  MedlineGoogle Scholar
• 16. Burton G, Charnock-Jones D, Jauniaux E. Regulation of vascular growth and function in the human placenta. Reproduction 138(6), 895–902 (2009).
  Medline CASGoogle Scholar
• 17. Fisher SJ. Why is placentation abnormal in preeclampsia? Am. J. Obstet. Gynecol. 213(4), S115–S122 (2015).
  MedlineGoogle Scholar
• 18. Romero R, Kusanovic JP, Chaiworapongsa T, Hassan SS. Placental bed disorders in pre-term labor, pre-term PROM, spontaneous abortion and abruptio placentae. Best Pract. Res. Clin. Obstet. Gynaecol. 25(3), 313–327 (2011).
  MedlineGoogle Scholar
• 19. Weiner E, Feldstein O, Tamayev L et al. Placental histopathological lesions in correlation with neonatal outcome in preeclampsia with and without severe features. Pregnancy Hypertens. 12, 6–10 (2018).
  MedlineGoogle Scholar
• 20. Silver RM. Examining the link between placental pathology, growth restriction, and stillbirth. Best Pract. Res. Clin. Obstet. Gynaecol. 49, 89–102 (2018).
  MedlineGoogle Scholar
• 21. Barker DJ. The developmental origins of chronic adult disease. Acta Paediatr. 93, 26–33 (2004).
  CASGoogle Scholar
• 22. Barker DJ. The developmental origins of well-being. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 359(1449), 1359–1366 (2004).
  Medline CASGoogle Scholar
• 23. Salafia C, Pezzullo J, Ghidini A, Lopez-Zeno J, Whittington S. Clinical correlations of patterns of placental pathology in pre-term preeclampsia. Placenta 19(1), 67–72 (1998). • Analyzing a database of nonanomalous singleton live births, they find links between severe maternal proteinuria and placental chronic inflammation and associations of lower platelet counts with placental abruption and infarct. Uteroplacental vascular lesions correlate with lower birthweight percentiles and lighter placentae, highlighting the intricate relationship between placental pathology and adverse pregnancy outcomes.
  Medline CASGoogle Scholar
• 24. Trudinger B, Cook C, Jones L, Giles W. A comparison of fetal heart rate monitoring and umbilical artery waveforms in the recognition of fetal compromise. Br. J. Obstet. Gynaecol. 93(2), 171–175 (1986).
  Medline CASGoogle Scholar
• 25. Trudinger BJ, Giles WB. Elaboration of stem villous vessels in growth restricted pregnancies with abnormal umbilical artery Doppler waveforms. Br. J. Obstet. Gynaecol. 103(5), 487–489 (1996).
  Medline CASGoogle Scholar
• 26. Gagnon R, Johnston L, Murotsuki J. Fetal placental embolization in the late-gestation ovine fetus: alterations in umbilical blood flow and fetal heart rate patterns. Am. J. Obstet. Gynecol. 175(1), 63–72 (1996).
  Medline CASGoogle Scholar
• 27. Phipps E, Prasanna D, Brima W, Jim B. Preeclampsia: updates in pathogenesis, definitions, and guidelines. Clin. J. Am. Soc. Nephrol. 11(6), 1102 (2016). •• Delves into pathogenesis, elucidating the roles of various factors such as angiogenic pathways, autoantibodies, nitric oxide and oxidative stress. The shift in viewing preeclampsia as a systemic disease with long-term cardiovascular implications is explored, leading to updated definitions, classification and treatment strategies, emphasizing improved care for at-risk women beyond childbirth.
  Medline CASGoogle Scholar
• 28. Redman CW, Sargent IL. Immunology of preeclampsia. Am. J. Reprod. Immunol. 63(6), 534–543 (2010).
  Medline CASGoogle Scholar
• 29. Redman CW, Sargent IL, Taylor RN. Immunology of normal pregnancy and preeclampsia. In: Chesley's Hypertensive Disorders in Pregnancy. Elsevier, London, UK 161–179 (2015).
  Google Scholar
• 30. Ridder A, Giorgione V, Khalil A, Thilaganathan B. Preeclampsia: the relationship between uterine artery blood flow and trophoblast function. Int. J. Mol. Sci. 20(13), 3263 (2019). • Contrary to conventional understanding, the study highlights emerging evidence suggesting that abnormal placental perfusion could lead to trophoblast impairment; it emphasizes the critical role of maternal cardiovascular function in the pathophysiology of preeclampsia, shedding new light on the complex interplay between maternal factors and placental health.
  MedlineGoogle Scholar
• 31. Burton G, Yung H, Murray A. Mitochondrial–endoplasmic reticulum interactions in the trophoblast: stress and senescence. Placenta 52, 146–155 (2017).
  Medline CASGoogle Scholar
• 32. Mayne BT, Leemaqz SY, Smith AK, Breen J, Roberts CT, Bianco-Miotto T. Accelerated placental aging in early onset preeclampsia pregnancies identified by DNA methylation. Epigenomics 9(3), 279–289 (2017).
  CASGoogle Scholar
• 33. Sohlberg S, Mulic-Lutvica A, Lindgren P, Ortiz-Nieto F, Wikström A-K, Wikström J. Placental perfusion in normal pregnancy and early and late preeclampsia: a magnetic resonance imaging study. Placenta 35(3), 202–206 (2014).
  Medline CASGoogle Scholar
• 34. Jung E, Romero R, Yeo L et al. The etiology of preeclampsia. Am. J. Obstet. Gynecol. 226(2), S844–S866 (2022).
  Medline CASGoogle Scholar
• 35. Sibai BM. Preeclampsia as a cause of pre-term and late pre-term (near-term) births. Semin. Perinatol. 30(1), 16–19 (2006).
  MedlineGoogle Scholar
• 36. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 51(4), 970–975 (2008).
  Medline CASGoogle Scholar
• 37. Redman CW, Staff AC. Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am. J. Obstet. Gynecol. 213(4), S9.e1–S9.e4 (2015).
  Medline CASGoogle Scholar
• 38. Burton GJ, Jauniaux E. Placental oxidative stress: from miscarriage to preeclampsia. J. Soc. Gynecol. Investig. 11(6), 342–352 (2004).
  Medline CASGoogle Scholar
• 39. McCowan LM, Figueras F, Anderson NH. Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy. Am. J. Obstet. Gynecol. 218(2), S855–S868 (2018).
  MedlineGoogle Scholar
• 40. Owens JA. Endocrine and substrate control of fetal growth: placental and maternal influences and insulin-like growth factors. Reprod. Fertil. Dev. 3(5), 501–517 (1991). •• Placental transfer capacity and utilization of substrates significantly influence substrate transfer from mother to fetus, orchestrated by factors like oxygen, glucose and IGF-I concentrations. Placental hormones and proteins further sculpt this delicate balance, ensuring optimal maternal metabolic adaptation and nourishment for fetal development during pregnancy.
  Medline CASGoogle Scholar
• 41. Vorherr H. Factors influencing fetal growth. Am. J. Obstet. Gynecol. 142(5), 577–588 (1982).
  Medline CASGoogle Scholar
• 42. Sharma D, Shastri S, Sharma P. Intrauterine growth restriction: antenatal and postnatal aspects. Clin. Med. Insights Pediatr. 10, doi:10.4137/CMPed.S40070 (2016).
  Google Scholar
• 43. Burton GJ, Jauniaux E. Pathophysiology of placental-derived fetal growth restriction. Am. J. Obstet. Gynecol. 218(2), S745–S761 (2018).
  Medline CASGoogle Scholar
• 44. Fowden A, Forhead A. Endocrine mechanisms of intrauterine programming. Reproduction 127(5), 515–526 (2004).
  Medline CASGoogle Scholar
• 45. Murphy VE, Smith R, Giles WB, Clifton VL. Endocrine regulation of human fetal growth: the role of the mother, placenta, and fetus. Endocr. Rev. 27(2), 141–169 (2006).
  MedlineGoogle Scholar
• 46. Agrogiannis GD, Sifakis S, Patsouris ES, Konstantinidou AE. Insulin-like growth factors in embryonic and fetal growth and skeletal development. Mol. Med. Rep. 10(2), 579–584 (2014).
  Medline CASGoogle Scholar
• 47. Netchine I, Azzi S, Le Bouc Y, Savage MO. IGF1 molecular anomalies demonstrate its critical role in fetal, postnatal growth and brain development. Best Pract. Res. Clin. Endocrinol. Metab. 25(1), 181–190 (2011).
  Medline CASGoogle Scholar
• 48. Morris RK, Bilagi A, Devani P, Kilby MD. Association of serum PAPP-A levels in first trimester with small for gestational age and adverse pregnancy outcomes: systematic review and meta-analysis. Prenat. Diagn. 37(3), 253–265 (2017).
  Medline CASGoogle Scholar
• 49. Bartels HC, Postle JD, Downey P, Brennan DJ. Placenta accreta spectrum: a review of pathology, molecular biology, and biomarkers. Dis. Markers 2018, 1–11(2018).
  Google Scholar
• 50. Morlando M, Collins S. Placenta accreta spectrum disorders: challenges, risks, and management strategies. Int. J. Womens Health 2022, 1033–1045 (2020).
  Google Scholar
• 51. Hecht JL, Baergen R, Ernst LM et al. Classification and reporting guidelines for the pathology diagnosis of placenta accreta spectrum (PAS) disorders: recommendations from an expert panel. Mod. Pathol. 33(12), 2382–2396 (2020).
  MedlineGoogle Scholar
• 52. Jauniaux E, Collins S, Burton GJ. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am. J. Obstet. Gynecol. 218(1), 75–87 (2018).
  MedlineGoogle Scholar
• 53. Linn RL, Miller ES, Lim G, Ernst LM. Adherent basal plate myometrial fibers in the delivered placenta as a risk factor for development of subsequent placenta accreta. Placenta 36(12), 1419–1424 (2015).
  MedlineGoogle Scholar
• 54. Büke B, Akkaya H, Demir S et al. Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta. J. Matern. Fetal Neonatal Med. 31(1), 59–62 (2018).
  MedlineGoogle Scholar
• 55. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2(12), 751–760 (2007).
  Medline CASGoogle Scholar
• 56. Fliedel L, Alhareth K, Mignet N, Fournier T, Andrieux K. Placental models for evaluation of nanocarriers as drug delivery systems for pregnancy associated disorders. Biomedicines 10(5), 936 (2022).
  Medline CASGoogle Scholar
• 57. Valero L, Alhareth K, Gil S et al. Nanomedicine as a potential approach to empower the new strategies for the treatment of preeclampsia. Drug Discov. Today 23(5), 1099–1107 (2018).
  MedlineGoogle Scholar
• 58. Burton G, Woods A, Jauniaux E, Kingdom J. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 30(6), 473–482 (2009).
  Medline CASGoogle Scholar
• 59. Adekiya TA, Kondiah PP, Choonara YE, Kumar P, Pillay V. A review of nanotechnology for targeted anti-schistosomal therapy. Front. Bioeng. Biotechnol. 8, 32 (2020).
  MedlineGoogle Scholar
• 60. Pritchard N, Kaitu'u-Lino Tu, Harris L, Tong S, Hannan N. Nanoparticles in pregnancy: the next frontier in reproductive therapeutics. Hum. Reprod. Update 27(2), 280–304 (2021).
  Medline CASGoogle Scholar
• 61. Alhareth K, Sancey L, Tsapis N, Mignet N. How should we plan the future of nanomedicine for cancer diagnosis and therapy. Int. J. Pharm. 532(2), 657–659 (2017).
  Medline CASGoogle Scholar
• 62. Slingerland M, Guchelaar H-J, Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov. Today 17(3–4), 160–166 (2012).
  Medline CASGoogle Scholar
• 63. King A, Ndifon C, Lui S et al. Tumor-homing peptides as tools for targeted delivery of payloads to the placenta. Sci. Adv. 2(5), e1600349 (2016).
  MedlineGoogle Scholar
• 64. Cureton N, Korotkova I, Baker B et al. Selective targeting of a novel vasodilator to the uterine vasculature to treat impaired uteroplacental perfusion in pregnancy. Theranostics 7(15), 3715 (2017).
  Medline CASGoogle Scholar
• 65. Beards F, Jones LE, Charnock J, Forbes K, Harris LK. Placental homing peptide-microRNA inhibitor conjugates for targeted enhancement of intrinsic placental growth signaling. Theranostics 7(11), 2940 (2017).
  Medline CASGoogle Scholar
• 66. Zhang B, Tan L, Yu Y et al. Placenta-specific drug delivery by trophoblast-targeted nanoparticles in mice. Theranostics 8(10), 2765 (2018).
  Medline CASGoogle Scholar
• 67. Trac N, Ashraf A, Giblin J, Prakash S, Mitragotri S, Chung EJ. Spotlight on genetic kidney diseases: a call for drug delivery and nanomedicine solutions. ACS Nano 17(7), 6165–6177 (2023).
  Medline CASGoogle Scholar
• 68. Morton PD, Ishibashi N, Jonas RA. Neurodevelopmental abnormalities and congenital heart disease: insights into altered brain maturation. Circ. Res. 120(6), 960–977 (2017).
  Medline CASGoogle Scholar
• 69. Carr H, Cnattingius S, Granath F, Ludvigsson JF, Edstedt Bonamy A-K. Pre-term birth and risk of heart failure up to early adulthood. J. Am. Coll. Cardiol. 69(21), 2634–2642 (2017).
  MedlineGoogle Scholar
• 70. Solimani F, Narenji F, Pourmohsen M, Khalrghinejad K, Mehran N. Cerebral palsy and patterns of magnetic resonance imaging (MRI): a review. Iran. Rehabil. J. 12(4), 59–64 (2014).
  Google Scholar
• 71. Abd Ellah N, Taylor L, Troja W et al. Development of non-viral, trophoblast-specific gene delivery for placental therapy. PLOS ONE 10(10), e0140879 (2015).
  MedlineGoogle Scholar
• 72. Dodd A, Natfji AA, Evangelinos A et al. Conjugation to PEG as a strategy to limit the uptake of drugs by the placenta: potential applications for drug administration in pregnancy. Mol. Pharm. 19(1), 345–353 (2021).
  MedlineGoogle Scholar
• 73. Kuna M, Waller JP, Logue OC, Bidwell GL III. Polymer size affects biodistribution and placental accumulation of the drug delivery biopolymer elastin-like polypeptide in a rodent pregnancy model. Placenta 72, 20–27 (2018).
  MedlineGoogle Scholar
• 74. N'Dea S, Nelson KM, Dang MN, Gleghorn JP, Day ES. Gold nanoparticle biodistribution in pregnant mice following intravenous administration varies with gestational age. Nanomed. Nanotechnol. Biol. Med. 36, 102412 (2021).
  Google Scholar
• 75. Muoth C, Großgarten M, Karst U et al. Impact of particle size and surface modification on gold nanoparticle penetration into human placental microtissues. Nanomedicine (Lond.) 12(10), 1119–1133 (2017).
  CASGoogle Scholar
• 76. Poulsen MS, Mose T, Maroun LL, Mathiesen L, Knudsen LE, Rytting E. Kinetics of silica nanoparticles in the human placenta. Nanotoxicology 9(Suppl. 1), 79–86 (2015).
  Medline CASGoogle Scholar
• 77. Alfaifi AA, Heyder RS, Bielski ER et al. Megalin-targeting liposomes for placental drug delivery. J. Control. Rel. 324, 366–378 (2020).
  Medline CASGoogle Scholar
• 78. Ho D, Leong JW, Crew RC et al. Maternal–placental–fetal biodistribution of multimodal polymeric nanoparticles in a pregnant rat model in mid and late gestation. Sci. Rep. 7(1), 2866 (2017).
  MedlineGoogle Scholar
• 79. Juch H, Nikitina L, Reimann S et al. Dendritic polyglycerol nanoparticles show charge dependent bio-distribution in early human placental explants and reduce hCG secretion. Nanotoxicology 12(2), 90–103 (2018).
  Medline CASGoogle Scholar
• 80. Menjoge AR, Rinderknecht AL, Navath RS et al. Transfer of PAMAM dendrimers across human placenta: prospects of its use as drug carrier during pregnancy. J. Control. Rel. 150(3), 326–338 (2011).
  Medline CASGoogle Scholar
• 81. Sibai B, Dekker G, Kupferminc M. Preeclampsia. Lancet 365(9461), 785–799 (2005).
  MedlineGoogle Scholar
• 82. McCarthy FP, Kenny LC. Hypertension in pregnancy. Obstet. Gynaecol. Reprod. Med. 22(6), 141–147 (2012).
  Google Scholar
• 83. Tranquilli A, Dekker G, Magee L et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 4(2), 97–104 (2014).
  Medline CASGoogle Scholar
• 84. Maynard SE, Min J-Y, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Investig. 111(5), 649–658 (2003).
  Medline CASGoogle Scholar
• 85. Gilbert JS, Verzwyvelt J, Colson D, Arany M, Karumanchi SA, Granger JP. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension 55(2), 380–385 (2010).
  Medline CASGoogle Scholar
• 86. Woods AK, Hoffmann DS, Weydert CJ et al. Adenoviral delivery of VEGF121 early in pregnancy prevents spontaneous development of preeclampsia in BPH/5 mice. Hypertension 57(1), 94–102 (2011).
  Medline CASGoogle Scholar
• 87. Logue OC, Mahdi F, Chapman H, George EM, Bidwell GL III. A maternally sequestered, biopolymer-stabilized vascular endothelial growth factor (VEGF) chimera for treatment of preeclampsia. J. Am. Heart Assoc. 6(12), e007216 (2017).
  MedlineGoogle Scholar
• 88. Alexander BT, Cockrell KL, Massey MB, Bennett WA, Granger JP. Tumor necrosis factor-α-induced hypertension in pregnant rats results in decreased renal neuronal nitric oxide synthase expression. Am. J. Hypertens. 15(2), 170–175 (2002).
  Medline CASGoogle Scholar
• 89. Yu J, Jia J, Guo X, Chen R, Feng L. Modulating circulating sFlt1 in an animal model of preeclampsia using PAMAM nanoparticles for siRNA delivery. Placenta 58, 1–8 (2017).
  MedlineGoogle Scholar
• 90. Turanov AA, Lo A, Hassler MR et al. RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat. Biotechnol. 36(12), 1164–1173 (2018).
  CASGoogle Scholar
• 91. Li L, Yang H, Chen P et al. Trophoblast-targeted nanomedicine modulates placental sFLT1 for preeclampsia treatment. Front. Bioeng. Biotechnol. 8, 64 (2020).
  MedlineGoogle Scholar
• 92. Suhag A, Berghella V. Intrauterine growth restriction (IUGR): etiology and diagnosis. Curr. Obstet. Gynecol. Rep. 2(2), 102–111 (2013).
  Google Scholar
• 93. Ferretti C, Bruni L, Dangles-Marie V, Pecking A, Bellet D. Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum. Reprod. Update 13(2), 121–141 (2007).
  Medline CASGoogle Scholar
• 94. Constância M, Hemberger M, Hughes J et al. Placental-specific IGF-II is a major modulator of placental and fetal growth. Nature 417(6892), 945–948 (2002).
  Medline CASGoogle Scholar
• 95. Forbes K, Westwood M, Baker PN, Aplin JD. Insulin-like growth factor I and II regulate the life cycle of trophoblast in the developing human placenta. Am. J. Physiol. Cell Physiol. 294(6), C1313–C1322 (2008).
  Medline CASGoogle Scholar
• 96. King A, Ndifon C, Lui S et al. Tumor-homing peptides as tools for targeted delivery of payloads to the placenta. Sci. Adv. 2(5), e1600349 (2016).
  MedlineGoogle Scholar
• 97. Beards F, Jones LE, Charnock J, Forbes K, Harris LK. Placental homing peptide-microRNA inhibitor conjugates for targeted enhancement of intrinsic placental growth signaling. Theranostics 7(11), 2940 (2017).
  Medline CASGoogle Scholar
• 98. Cureton N, Korotkova I, Baker B et al. Selective targeting of a novel vasodilator to the uterine vasculature to treat impaired uteroplacental perfusion in pregnancy. Theranostics 7(15), 3715 (2017).
  Medline CASGoogle Scholar
• 99. Lyall F, Greer I, Young A, Myatt L. Nitric oxide concentrations are increased in the feto–placental circulation in intrauterine growth restriction. Placenta 17(2–3), 165–168 (1996).
  Medline CASGoogle Scholar
• 100. Myatt L, Eis A, Brockman D, Greer I, Lyall F. Endothelial nitric oxide synthase in placental villous tissue from normal, pre-eclamptic and intrauterine growth restricted pregnancies. Hum. Reprod. 12(1), 167–172 (1997).
  Medline CASGoogle Scholar
• 101. Morgan TK. Role of the placenta in pre-term birth: a review. Am. J. Perinatol. 33(03), 258–266 (2016).
  MedlineGoogle Scholar
• 102. Blackwell SC, Gyamfi-Bannerman C, Biggio JR Jr et al. 17-OHPC to prevent recurrent pre-term birth in singleton gestations (PROLONG study): a multicenter, international, randomized double-blind trial. Am. J. Perinatol. 37(02), 127–136 (2020).
  MedlineGoogle Scholar
• 103. Rubin R. Confirmatory trial for drug to prevent pre-term birth finds no benefit, so why is it still prescribed? J. Am. Med. Assoc. 323(13), 1229–1232 (2020).
  Google Scholar
• 104. Norman JE, Marlow N, Messow C-M et al. Vaginal progesterone prophylaxis for pre-term birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet 387(10033), 2106–2116 (2016).
  Medline CASGoogle Scholar
• 105. Gandell DL, Randell MD, Gudeman JL. FDA approved vs pharmacy compounded 17-OHPC – current issues for obstetricians to consider in reducing recurrent pre-term birth. Curr. Med. Res. Opin. 36(8), 1393–1401 (2020).
  Medline CASGoogle Scholar
• 106. Refuerzo JS, Leonard F, Bulayeva N et al. Uterus-targeted liposomes for pre-term labor management: studies in pregnant mice. Sci. Rep. 6(1), 34710 (2016).
  Medline CASGoogle Scholar
• 107. Refuerzo JS, Alexander JF, Leonard F, Leon M, Longo M, Godin B. Liposomes: a nanoscale drug carrying system to prevent indomethacin passage to the fetus in a pregnant mouse model. Am. J. Obstet. Gynecol. 212(4), 508.e501–508.e507 (2015).
  Google Scholar
• 108. Paul JW, Hua S, Ilicic M et al. Drug delivery to the human and mouse uterus using immunoliposomes targeted to the oxytocin receptor. Am. J. Obstet. Gynecol. 216(3), 283.e281–283.e214 (2017).
  Google Scholar
• 109. Greenwood IA, Yeung S, Tribe R, Ohya S. Loss of functional K⁺ channels encoded by ether-à-go-go-related genes in mouse myometrium prior to labour onset. J. Physiol. 587(10), 2313–2326 (2009).
  Medline CASGoogle Scholar
• 110. Bulletti C, de Ziegler D, Flamigni C et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum. Reprod. 12(5), 1073–1079 (1997).
  Medline CASGoogle Scholar
• 111. Zierden HC, Ortiz JI, DeLong K et al. Enhanced drug delivery to the reproductive tract using nanomedicine reveals therapeutic options for prevention of pre-term birth. Sci. Transl. Med. 13(576), eabc6245 (2021).
  Medline CASGoogle Scholar
• 112. Wang B, Navath RS, Menjoge AR et al. Inhibition of bacterial growth and intramniotic infection in a guinea pig model of chorioamnionitis using PAMAM dendrimers. Int. J. Pharm. 395(1–2), 298–308 (2010).
  Medline CASGoogle Scholar
• 113. Lei J, Rosenzweig JM, Mishra MK et al. Maternal dendrimer-based therapy for inflammation-induced pre-term birth and perinatal brain injury. Sci. Rep. 7(1), 6106 (2017).
  MedlineGoogle Scholar
• 114. Epps TH III, Vi T, Sullivan MO. Design and development of a robust photo-responsive block copolymer framework for tunable nucleic acid delivery and efficient gene silencing. Polymer J. 50(8), 711–723 (2018).
  CASGoogle Scholar
• 115. Riley RS, Dang MN, Billingsley MM, Abraham B, Gundlach L, Day ES. Evaluating the mechanisms of light-triggered siRNA release from nanoshells for temporal control over gene regulation. Nano Lett. 18(6), 3565–3570 (2018).
  Medline CASGoogle Scholar
• 116. Li C, Liu X, Liu Y et al. Glucose and H₂O₂ dual-sensitive nanogels for enhanced glucose-responsive insulin delivery. Nanoscale 11(18), 9163–9175 (2019).
  Medline CASGoogle Scholar
• 117. Zhang C, Hong S, Liu M-D et al. pH-sensitive MOF integrated with glucose oxidase for glucose-responsive insulin delivery. J. Control. Rel. 320, 159–167 (2020).
  Medline CASGoogle Scholar
• 118. Volpatti LR, Matranga MA, Cortinas AB et al. Glucose-responsive nanoparticles for rapid and extended self-regulated insulin delivery. ACS Nano 14(1), 488–497 (2019).
  MedlineGoogle Scholar
• 119. Van Calsteren K, Heyns L, Smet FD et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J. Clin. Oncol. 28(4), 683–689 (2010).
  MedlineGoogle Scholar
• 120. Stensheim H, Møller B, van Dijk T, Fosså SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J. Clin. Oncol. 27(1), 45–51 (2009).
  MedlineGoogle Scholar
• 121. Wang S-W, Ma L-L, Huang S, Liang L, Zhang J-R. Role of cervical cerclage and vaginal progesterone in the treatment of cervical incompetence with/without pre-term birth history. Chin. Med. J. 129(22), 2670–2675 (2016).
  MedlineGoogle Scholar
• 122. Hassan S, Romero R, Vidyadhari D et al. Vaginal progesterone reduces the rate of pre-term birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet. Gynecol. 38(1), 18–31 (2011).
  Medline CASGoogle Scholar
• 123. Kistner RW. The treatment of endometriosis by inducing pseudopregnancy with ovarian hormones: a report of fifty-eight cases. Fertil. Steril. 10(6), 539–556 (1959).
  Google Scholar
• 124. Yuan P, Huang Y, Wu H, Teng Z, Zhang J, Xin X. Induction of a local pseudo-pregnancy via levonorgestrel-loaded microspheres for the treatment of endometriosis in a rabbit model. Hum. Reprod. 25(2), 462–469 (2010).
  Medline CASGoogle Scholar
• 125. Shetty AN, Pautler R, Ghaghada K et al. A liposomal Gd contrast agent does not cross the mouse placental barrier. Sci. Rep. 6(1), 27863 (2016).
  Medline CASGoogle Scholar
• 126. Badachhape AA, Kumar A, Ghaghada KB et al. Preclinical magnetic resonance imaging of retroplacental clear space throughout gestation. Placenta 77, 1–7 (2019).
  MedlineGoogle Scholar
• 127. Badachhape AA, Devkota L, Stupin IV et al. Nanoparticle contrast-enhanced T1-mapping enables estimation of placental fractional blood volume in a pregnant mouse model. Sci. Rep. 9(1), 18707 (2019).
  Medline CASGoogle Scholar
• 128. Ghaghada KB, Starosolski ZA, Bhayana S et al. Preclinical evaluation of a nanoparticle-based blood-pool contrast agent for MR imaging of the placenta. Placenta 57, 60–70 (2017).
  Medline CASGoogle Scholar